Prof. Xianjun Yu 虞先濬
Chief Physician, Professor
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of benign and malignant tumors of the pancreas, neuroendocrine tumors, gastrointestinal stromal tumors, liver, gallbladder, spleen, and duodenum.
Dr. Yu is Dean of Fudan University Shanghai Cancer Center and Director of the Shanghai and Fudan University Pancreatic Tumor Institute. With over 20 years of surgical experience, Dr. Yu completed postdoctoral research and clinical training at Baylor College of Medicine and MD Anderson Cancer Center. Dr. Yu founded the hospital’s Pancreatic Surgery Department in 2010 and has performed over 3,000 pancreatic tumor surgeries.
Professional roles
- Chair, Pancreatic Cancer Professional Committee, China Anti-Cancer Association
- Leader, CSPAC China Pancreatic Cancer Multidisciplinary Collaboration Group
- Member, Pancreatic Surgery Group, Surgical Branch, Chinese Medical Association
- Standing Committee Member, Pancreatic Disease Professional Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Yu Xianjun). Papers usually list the name as Xianjun Yu or Yu X.
Selected publications
426 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Cell, 2026 (senior author): Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. PubMed 42748921
- Ann Surg Oncol, 2026 (senior author): ASO Visual Abstract: Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video). PubMed 42298081
- Ann Surg Oncol, 2026 (senior author): Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video). PubMed 42201493
- Cancer Cell, 2026 (senior author): Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. PubMed 42276047
- Nat Commun, 2026 (senior author): Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer. PubMed 42209505
- Int J Surg, 2025 (senior author): Main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic enucleation: a long-term metabolic outcome from a prospective cohort study (CSPAC-MIEN-1). PubMed 40679988
- Cell Rep Med, 2025 (senior author): A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. PubMed 40975066
- Gastroenterology, 2025 (senior author): Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. PubMed 40158738
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion